Search

Structures of the HER2–HER3–NRG1β complex reveal a dynamic dimer

4.7 (586) · $ 30.99 · In stock

Structures of the HER2–HER3–NRG1β complex reveal a dynamic dimer
RCSB PDB - 7MN5: Structure of the HER2/HER3/NRG1b Heterodimer

RCSB PDB - 7MN5: Structure of the HER2/HER3/NRG1b Heterodimer

Purification, characterization, and reconstruction of the near

Purification, characterization, and reconstruction of the near

Cryo-EM analyses of wild-type and oncogenic KIT mutants reveal structural  oncogenic plasticity and a novel “Achilles heel” for therapeutic  intervention

Cryo-EM analyses of wild-type and oncogenic KIT mutants reveal structural oncogenic plasticity and a novel “Achilles heel” for therapeutic intervention

Avoiding arm contact  Nature Chemical Biology

Avoiding arm contact Nature Chemical Biology

IJMS, Free Full-Text

IJMS, Free Full-Text

Molecular dynamics simulations of asymmetric heterodimers of HER1/HER2  complexes

Molecular dynamics simulations of asymmetric heterodimers of HER1/HER2 complexes

Crystal structure of the human TβR2 ectodomain–TGF-β3 complex

Crystal structure of the human TβR2 ectodomain–TGF-β3 complex

Structure and dynamics of the EGFR/HER2 heterodimer

Structure and dynamics of the EGFR/HER2 heterodimer

Targeting HER2 and FGFR-positive cancer cells with a bispecific cytotoxic  conjugate combining anti-HER2 Affibody and FGF2 - ScienceDirect

Targeting HER2 and FGFR-positive cancer cells with a bispecific cytotoxic conjugate combining anti-HER2 Affibody and FGF2 - ScienceDirect

Structural dynamics of the active HER4 and HER2/HER4 complexes is

Structural dynamics of the active HER4 and HER2/HER4 complexes is

Paul Klauser (@PaulKlauser) / X

Paul Klauser (@PaulKlauser) / X

Structural dynamics of the active HER4 and HER2/HER4 complexes is

Structural dynamics of the active HER4 and HER2/HER4 complexes is

PDF] Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex

PDF] Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex

Targeting HER2 and FGFR-positive cancer cells with a bispecific cytotoxic  conjugate combining anti-HER2 Affibody and FGF2 - ScienceDirect

Targeting HER2 and FGFR-positive cancer cells with a bispecific cytotoxic conjugate combining anti-HER2 Affibody and FGF2 - ScienceDirect